Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00604006
Registration number
NCT00604006
Ethics application status
Date submitted
16/01/2008
Date registered
29/01/2008
Date last updated
4/06/2015
Titles & IDs
Public title
SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)
Query!
Scientific title
SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)
Query!
Secondary ID [1]
0
0
CP-02/07
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Heart Failure
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Coronary heart disease
Query!
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Spironolactone
Treatment: Drugs - Placebo
Experimental: Group A -
Placebo comparator: Group B -
Treatment: Drugs: Spironolactone
25 mg tablets (placed in capsules for blinding) once daily.
Treatment: Drugs: Placebo
Placebo (lactose in capsules for blinding) once daily
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Effectiveness of Spironolactone in preventing heart failure
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
1 year and 3 year
Query!
Primary outcome [2]
0
0
Cost effectiveness of Spironolactone prevention
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
3 years
Query!
Secondary outcome [1]
0
0
Development of evidence of LV dysfunction, either systolic or diastolic, on echocardiography and/or symptomatic heart failure
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
1 year and 3 year
Query!
Secondary outcome [2]
0
0
Change in 6 minute walk test between the two groups
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
1 year and 3 years
Query!
Secondary outcome [3]
0
0
Change in quality of life between the two groups
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
1 year and 3 year
Query!
Secondary outcome [4]
0
0
Change in left ventricular remodelling parameters
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
1 year and 3 years
Query!
Eligibility
Key inclusion criteria
1. Was recruited to SCREEN-HF
2. Has provided informed consent
Query!
Minimum age
60
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
1. Uncorrected hyperkalaemia
2. eGFR < 30 ml/min
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/01/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
20
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Alfred Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3004 - Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Monash University
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
National Heart Foundation, Australia
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Individuals who were a part of the investigators Screen-HF study (NCT00400257) whose BNP level are in the top quintile will be offered participation in this study. Participants will be randomised to receive either spironolactone or placebo for three years. Participants will then be monitored for indications of heart failure. It is anticipated that the medication will reduce the development of heart failure in this group.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00604006
Query!
Trial related presentations / publications
Campbell DJ, Coller JM, Gong FF, McGrady M, Boffa U, Shiel L, Liew D, Stewart S, Owen AJ, Krum H, Reid CM, Prior DL. Kidney age - chronological age difference (KCD) score provides an age-adapted measure of kidney function. BMC Nephrol. 2021 Apr 26;22(1):152. doi: 10.1186/s12882-021-02324-y. Gong FF, Jelinek MV, Castro JM, Coller JM, McGrady M, Boffa U, Shiel L, Liew D, Wolfe R, Stewart S, Owen AJ, Krum H, Reid CM, Prior DL, Campbell DJ. Risk factors for incident heart failure with preserved or reduced ejection fraction, and valvular heart failure, in a community-based cohort. Open Heart. 2018 Jul 23;5(2):e000782. doi: 10.1136/openhrt-2018-000782. eCollection 2018. Erratum In: Open Heart. 2018 Sep 5;5(2):e000782corr1. doi: 10.1136/openhrt-2018-000782corr1.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Henry Krum, MBBS FRACP PhD
Query!
Address
0
0
Monash University / Alfred Hospital
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT00604006
Download to PDF